Login to Your Account



Canadian Stem Cell Approval Could Be the First of Many

By Catherine Shaffer
Staff Writer

Monday, May 21, 2012
Osiris Therapeutics Inc. won a double victory today with the first ever marketing approval for a manufactured stem cell product and the first therapy for graft-vs.-host disease (GvHD). Health Canada issued marketing authorization for Osiris's stem cell therapy Prochymal (remestemcel-L) for GvHD in children.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription